NO975309L - Anvendelse av rivavirin og alfa-interferon til behandling av hepatitt C - Google Patents

Anvendelse av rivavirin og alfa-interferon til behandling av hepatitt C

Info

Publication number
NO975309L
NO975309L NO975309A NO975309A NO975309L NO 975309 L NO975309 L NO 975309L NO 975309 A NO975309 A NO 975309A NO 975309 A NO975309 A NO 975309A NO 975309 L NO975309 L NO 975309L
Authority
NO
Norway
Prior art keywords
rivavirin
hepatitis
treatment
alpha interferon
interferon
Prior art date
Application number
NO975309A
Other languages
English (en)
Other versions
NO975309D0 (no
Inventor
Janice K Albrecht
Paul C Grint
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO975309D0 publication Critical patent/NO975309D0/no
Publication of NO975309L publication Critical patent/NO975309L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO975309A 1995-05-19 1997-11-19 Anvendelse av rivavirin og alfa-interferon til behandling av hepatitt C NO975309L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/444,584 US6387365B1 (en) 1995-05-19 1995-05-19 Combination therapy for chronic hepatitis C infection
PCT/US1996/006552 WO1996036351A1 (en) 1995-05-19 1996-05-15 Use of ribavirin and interferon alpha for the treatment of hepatitis c

Publications (2)

Publication Number Publication Date
NO975309D0 NO975309D0 (no) 1997-11-19
NO975309L true NO975309L (no) 1997-11-19

Family

ID=23765515

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975309A NO975309L (no) 1995-05-19 1997-11-19 Anvendelse av rivavirin og alfa-interferon til behandling av hepatitt C

Country Status (15)

Country Link
US (2) US6387365B1 (no)
EP (2) EP0707855A3 (no)
JP (1) JPH10506640A (no)
KR (1) KR19990014925A (no)
CN (1) CN1190895A (no)
AU (1) AU5919296A (no)
BR (1) BR9608758A (no)
CA (1) CA2221314A1 (no)
CZ (1) CZ365497A3 (no)
HU (1) HUP9802324A3 (no)
NO (1) NO975309L (no)
NZ (1) NZ309217A (no)
PL (1) PL323477A1 (no)
SK (1) SK155997A3 (no)
WO (1) WO1996036351A1 (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
PT858343E (pt) * 1995-11-02 2004-07-30 Schering Corp Terapia por infusao continua de uma dose baixa de citoquina
US20020137696A1 (en) * 1996-01-23 2002-09-26 Robert Tam Specific modulation of TH1/TH2 cytokine expression by ribavirin in activated T-lymphocytes
JP3416147B2 (ja) * 1996-01-23 2003-06-16 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド 活性化ｔリンパ球におけるリバビリン及びリバビリン類似体によるｔｈ１型／ｔｈ２型サイトカインの発現の調節
JP2000506839A (ja) * 1996-02-28 2000-06-06 アイエフアイ ノスチチュート ファルマコテラピコ イタリアーノ ソシエタ ペル アチオニ 天然ヒトα―インターフェロンを含む薬剤組成物
WO1998019670A2 (en) * 1996-11-01 1998-05-14 Thomas Najarian Combination therapy of hepatitis c infections
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
DE69801970T2 (de) * 1997-09-21 2002-06-13 Schering Corp Kombinationstherapie zur Entfernung von nachweisbarer HCV-RNS in Patienten mit chronischer Hepatitis C-Infektion
CA2323849C (en) * 1997-12-22 2002-06-11 Schering Corporation Orally administrable solid ribavirin dosage forms and process for making them
ES2172288T3 (es) * 1998-05-15 2002-09-16 Schering Corp Terapia de combinacion que comprende ribavirina e interferon alfa en pacientes que no han sido sometidos a tratamiento antiviral y que tienen infeccion cronica de hepatitis c.
ES2251196T3 (es) * 1998-06-08 2006-04-16 F. Hoffmann-La Roche Ag Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica.
CN1324250A (zh) * 1998-09-04 2001-11-28 维洛药品公司 治疗或预防病毒感染及其所致疾病的方法
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
PL347268A1 (en) * 1998-10-16 2002-03-25 Schering Corp Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
AR022116A1 (es) * 1998-12-18 2002-09-04 Schering Corp Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
JP2003507322A (ja) * 1998-12-18 2003-02-25 シェリング・コーポレーション リバビリン−ＰＥＧ化インターフェロン−α誘発ＨＣＶ併用治療
CN1420723A (zh) * 1999-12-23 2003-05-28 Icn药品公司 L－核苷、l－核苷酸及其类似物的组合物和方法
CA2405709A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US6924270B2 (en) 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
KR20030043924A (ko) * 2000-08-02 2003-06-02 오르토-맥네일 파마슈티칼, 인코퍼레이티드 에리트로포이에틴 투여에 의한 개선된 항-바이러스 및항-종양 화학 요법
US6946125B2 (en) * 2000-08-23 2005-09-20 The New York Hospital Medical Center Of Queens Methods of treating West Nile virus infection
US20060024270A1 (en) * 2000-08-23 2006-02-02 The New York Hospital Medical Center Of Queens Compositions and methods for preventing or treating encephalitis with interferon
BR0114636A (pt) * 2000-10-18 2004-02-10 Schering Corp Terapia combinada para hcv de interferon-alfa peguilado/ribavirina
US6720000B2 (en) 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
US20030143191A1 (en) * 2001-05-25 2003-07-31 Adam Bell Chemokine beta-1 fusion proteins
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
CA2471363C (en) * 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US8476254B2 (en) 2002-07-02 2013-07-02 Corcept Therapeutics, Inc. Methods for treating psychosis associated with interferson-α therapy
EP1539960B1 (en) * 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
US7538094B2 (en) 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
JP2004143113A (ja) * 2002-10-25 2004-05-20 Shinya Nakajima インターフェロン製剤及びその投与システム
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
WO2004084796A2 (en) * 2003-03-28 2004-10-07 Pharmasset Ltd. Compounds for the treatment of flaviviridae infections
EP2368900A3 (en) 2003-07-18 2012-07-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
JPWO2006033453A1 (ja) * 2004-09-22 2008-05-15 学校法人順天堂 インターフェロン作用物質の活性増強剤
US7723310B2 (en) 2004-10-18 2010-05-25 Three Rivers Pharmaceuticals, Llc Large dose ribavirin formulations
EP1850862A2 (en) * 2005-01-19 2007-11-07 Avigenics, Inc. Methods of treating disease with glycosylated interferon
JP5034944B2 (ja) * 2005-07-27 2012-09-26 味の素株式会社 インターフェロン作用物質の活性増強剤
WO2008088581A2 (en) * 2006-08-02 2008-07-24 United Therapeutics Corporation Liposome treatment of viral infections
US20080131398A1 (en) * 2006-08-21 2008-06-05 United Therapeutics Corporation Combination therapy for treatment of viral infections
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
US8137661B2 (en) * 2007-07-25 2012-03-20 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of HCV infections using same
CN102046151A (zh) * 2008-03-26 2011-05-04 牛津大学 靶向内质网的脂质体
NZ591030A (en) * 2008-09-17 2012-10-26 Boehringer Ingelheim Int Combination of hcv ns3 protease inhibitor with interferon and ribavirin
EP2410989A2 (en) * 2009-03-27 2012-02-01 The Chancellor, Masters and Scholars of the University of Oxford Cholesterol level lowering liposomes
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
NZ598465A (en) 2009-10-30 2013-10-25 Boehringer Ingelheim Int Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
BR112014005617A2 (pt) 2011-10-21 2017-06-13 Abbvie Inc tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv
ES2572329B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
US20140363396A1 (en) * 2012-02-01 2014-12-11 Kadmon Pharmaceuticals Llc Once daily treatment of hepatitis c with ribavirin and taribavirin
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof

Also Published As

Publication number Publication date
WO1996036351A1 (en) 1996-11-21
EP1005868A1 (en) 2000-06-07
US6299872B1 (en) 2001-10-09
SK155997A3 (en) 1998-10-07
EP0707855A3 (en) 1996-11-27
HUP9802324A3 (en) 2001-04-28
CN1190895A (zh) 1998-08-19
CA2221314A1 (en) 1996-11-21
NZ309217A (en) 2000-08-25
CZ365497A3 (cs) 1998-07-15
EP0707855A2 (en) 1996-04-24
KR19990014925A (ko) 1999-02-25
JPH10506640A (ja) 1998-06-30
PL323477A1 (en) 1998-03-30
AU5919296A (en) 1996-11-29
MX9708885A (es) 1998-03-31
US6387365B1 (en) 2002-05-14
NO975309D0 (no) 1997-11-19
BR9608758A (pt) 1999-07-06
HUP9802324A2 (hu) 1999-05-28

Similar Documents

Publication Publication Date Title
NO975309L (no) Anvendelse av rivavirin og alfa-interferon til behandling av hepatitt C
FI950587A0 (fi) Endotoksiinimyrkytyksen ennaltaehkäisyssä ja hoidossa käyttökelpoisia menetelmiä
NO972236D0 (no) Dihydropyrimidiner og anvendelse derav
DK1174135T3 (da) Farmaceutisk sammensætning omfattende pioglitazon og glimepirid til anvendelse i behandling af diabetes
NO953991D0 (no) Ultrasomisk og elektro-kirurgisk håndstykke av piezotype
DK1087778T3 (da) Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
AU6588598A (en) Treatment of hepatitis b infection with thymosin alpha 1 and famciclovir
NO984094L (no) Utladningsreaktor og anvendelse av samme
DK0804078T3 (da) Sammensætning og anvendelse deraf
NO971900D0 (no) Blandinger og behandling av multippel sklerose
NO922231D0 (no) Katalysatorsystem for polymerisering av 1-olefiner og katalysatorkomponent for anvendelse i dette
DK0898566T3 (da) Substituerede benzylaminer og anvendelse deraf til behandling af depression
DK139393D0 (da) Laegetermometer med digitalt og talende display
NO982463D0 (no) Anvendelse av en kombinasjon av pentoksyfyllin og type I-interferoner til behandling av multippel sklerose
DK0548520T3 (da) Fremgangsmåde til fremstilling af 2-alkoxymethylacrolein og dets anvendelse til fremstilling af 3-alkoxymethylquinoliner
DE59306085D1 (de) Haar- und körperbehandlungsmittel
NO981719D0 (no) Anvendelse av protein S-100b i medisiner og medisiner inneholdende protein S-100b
FI1031U1 (fi) En troakar
NO942686D0 (no) Anvendelse av 3-arylindol- og 3-arylindazolderivater ved behandling av psykoser
NO952194D0 (no) Spirofuranonderivater og deres anvendelse ved behandling av neurodegenerative sykdommer
KR950005392U (ko) 인체의 안면과 뒷머리 방한 덮개
KR940002718U (ko) 치질예방 및 치료기
DK55992D0 (da) Vaterpas med lyd og lys
KR940018880U (ko) 의자용 등받이와 팔꿈치 걸치게의 결착구조
KR960018392U (ko) 손가방 장치겸용 가스분사기

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application